Babu P Subash, Stanely Mainzen Prince P
Department of Biochemistry, Annamalai University, Annamalai Nagar-608 002, Tamil Nadu, India.
J Pharm Pharmacol. 2004 Nov;56(11):1435-42. doi: 10.1211/0022357044607.
Hyponidd is a herbomineral formulation composed of the extracts of ten medicinal plants ( Momordica charantia, Melia azadirachta, Pterocarpus marsupium, Tinospora cordifolia , Gymnema sylvestre, Enicostemma littorale, Emblica officinalis, Eugenia jambolana, Cassia auriculata and Curcuma longa). We have investigated hyponidd for its possible antihyperglycaemic and antioxidant effect in diabetic rats. Rats were rendered diabetic by streptozotocin (STZ) (45 mg kg(-1) body weight). Oral administration of hyponidd (100 mg kg(-1) and 200 mg kg(-1)) for 45 days resulted in significant lowered levels of blood glucose and significant increased levels of hepatic glycogen and total haemoglobin. An oral glucose tolerance test was also performed in experimental diabetic rats in which there was a significant improvement in blood glucose tolerance in the rats treated with hyponidd. Hyponidd administration also decreased levels of glycosylated haemoglobin, plasma thiobarbituric acid reactive substances, hydroperoxides, ceruloplasmin and alpha-tocopherol in diabetic rats. Plasma reduced glutathione and vitamin C were significantly elevated by oral administration of hyponidd. The effect of hyponidd at a dose of 200 mg kg(-1) was more effective than glibenclamide (600 microg kg(-1)) in restoring the values to near normal. The results showed that hyponidd exhibits antihyperglycaemic and antioxidant activity in STZ-induced diabetic rats.
Hyponidd是一种草药-矿物质制剂,由十种药用植物(苦瓜、印楝、阔叶紫檀、心叶地锦、匙羹藤、海滨千日红、余甘子、蒲桃、耳叶决明和姜黄)的提取物组成。我们研究了Hyponidd对糖尿病大鼠可能的降血糖和抗氧化作用。通过链脲佐菌素(STZ)(45 mg kg(-1)体重)使大鼠患糖尿病。口服Hyponidd(100 mg kg(-1)和200 mg kg(-1))45天导致血糖水平显著降低,肝糖原和总血红蛋白水平显著升高。还对实验性糖尿病大鼠进行了口服葡萄糖耐量试验,结果显示用Hyponidd治疗的大鼠的血糖耐量有显著改善。给予Hyponidd还降低了糖尿病大鼠的糖化血红蛋白、血浆硫代巴比妥酸反应性物质、氢过氧化物、铜蓝蛋白和α-生育酚水平。口服Hyponidd可使血浆还原型谷胱甘肽和维生素C显著升高。在将各项指标恢复至接近正常水平方面,200 mg kg(-1)剂量的Hyponidd比格列本脲(600 μg kg(-1))更有效。结果表明,Hyponidd在STZ诱导的糖尿病大鼠中表现出降血糖和抗氧化活性。